No phaseTerminated
Clinical Implication of Atrial Fibrillation Detection Using Wearable Device in Patients With Cryptogenic Stroke (CANDLE-AF)
Clinical Implication of Atrial Fibrillation Detection Using Wearable Device in Patients With Cryptogenic Stroke - The Comparison Between Short-term Continuous Patch and Long-term Discontinuous Monitoring
- Sponsor
- Ewha Womans University Mokdong Hospital (Academic or other)
- Enrolment
- 338 enrolled
- Conditions
- Atrial Fibrillation; Ischemic Stroke; Transient Ischemic Attack
- Interventions
- Ambulatory Holter monitoring; Discontinuous monitoring; Continuous single-lead ECG Patch
- Ages
- adults, older adults
- Registry
- NCT04624646, KCT0005592
Full record on ClinicalTrials.gov
From the registry
Atrial fibrillation (AF) detected after ischemic stroke has immediate therapeutic implications, because it prompts a switch from antiplatelet to anticoagulant therapy. The conventional method used to screen for AF in patients whose stroke has no identified cause (cryptogenic stroke) is 24-hour Holter monitoring. CANDLE-AF is a multicenter, open-label, randomized trial comparing three noninvasive monitoring strategies over 12 months in patients with cryptogenic ischemic stroke or transient ischemic attack and no known AF: physician-directed standard care (at least one 24- to 72-hour Holter recording), scheduled 72-hour single-lead patch ECG monitoring repeated at 1, 3, 6, and 12 months, and twice-daily 30-second handheld single-lead ECG recording with a smartphone-based device for 12 months. The primary outcome is detection of AF lasting 30 seconds or longer within 12 months.
Primary outcomes
- Detection of atrial fibrillation lasting 30 seconds or longer
History
Last registry update
Primary completion
Started
Registered